Table 1.
Characteristics baseline of patients in the total cohort
| Development Cohort (226) | Validation cohort (51) | P value | ||
|---|---|---|---|---|
| Training Set (164) | Test Set (62) | |||
| Age | 0.543 | |||
| Mean ± SD | 61.1 ± 8.7 | 63.9 ± 6.4 | 60.7 ± 9.2 | |
| Gender | 0.017 | |||
| Male (%) | 80(48.8) | 35(56.5) | 36(70.6) | |
| Female (%) | 84(51.2) | 27(43.5) | 15(29.4) | |
| Pathological TNM stage | 0.319 | |||
| IA (%) | 102(62.2) | 38(43.5) | 36(70.6) | |
| IB (%) | 62(37.8) | 24(56.5) | 15(29.4) | |
| Grade stage | 0.062 | |||
| 1(%) | 87(53.1) | 35(56.5) | 31(60.8) | |
| 2(%) | 15(9.1) | 9(14.5) | 10(19.6) | |
| 3(%) | 62(37.8) | 18(29.0) | 10(19.6) | |
| STAS | 0.099 | |||
| Yes (%) | 91(55.5) | 27(43.5) | 26(51.0) | |
| No (%) | 73(44.5) | 35(56.5) | 25(49.0) | |
| RFS status | - | |||
| Relapse (%) | 25(15.2) | 8(12.9) | 10(19.6) | |
| No relapse (%) | 139(84.8) | 54(87.1) | 41(80.4) | |
| RFS time (Month) | - | |||
| Median (IQR) | 40.2(34.5–51.9) | 40.9(35.5–50.5) | 38.7(35.4–40.6) | |
SD Standard deviation, STAS Spread through air spaces, RFS Recurrence free survival, IQR Interquartile range